Toxicity monitoring periods could be halved for patients who receive CAR-T therapy for diffuse large B-cell lymphoma (DLBCL), according to a new study.
The treatment is associated with two serious side-effects, cytokine release syndrome (CRS) and...
11 months ago
Being a non-malignant haematologist, I have always hated the term non-malignant! Even though I’m told by those who know me that I am not malignant, I don’t think anything (or anyone) should be defined by what it isn’t. I know I’m not alone in this...
11 months ago
